Back to top

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

Tvardi Therapeutics ( ($TVRD) ) has shared an update. On July 7, 2026, Tvardi Therapeutics reported Phase 1 results for TTI-109, a next-generation ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Tvardi Therapeutics, Inc. (TVRD)